Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ORANGE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced leadership updates that further strengthen the organization as the company continues to...
-
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines...
-
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter...
-
Total Revenue Growth of 23.7% Year Over Year in the First Quarter Same Store Sales Growth of 5.2% Year Over Year in the First Quarter Opened 9 New Stores in the First Quarter SCOTTSDALE, Ariz., May...
-
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Timeline for submission of NDA of deucrictibant IR for the on-demand...
-
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of...
-
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core...
-
Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for...
-
Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE...
-
– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance...